Atea Pharmaceuticals (AVIR, Financial) has announced plans to showcase the comprehensive results from its Phase 2 clinical trial of an innovative hepatitis C treatment during the European Association for the Study of the Liver (EASL) Congress 2025. This event will unfold in Amsterdam, Netherlands, from May 7 to 10.
The study focuses on a combined regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor. Alongside the primary findings, data highlighting the pharmacokinetic and safety aspects of the treatment will also be shared, underlining its potential in addressing the diverse needs of hepatitis C patients.
Following the successful completion of the Phase 2 trial, Atea Pharmaceuticals is gearing up for its global Phase 3 program. This new phase aims to confirm the efficacy of the bemnifosbuvir and ruzasvir regimen, which the company anticipates could significantly increase the number of hepatitis C patients who receive treatment and achieve a cure.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 1 analysts, the average target price for Atea Pharmaceuticals Inc (AVIR, Financial) is $6.00 with a high estimate of $6.00 and a low estimate of $6.00. The average target implies an upside of 109.06% from the current price of $2.87. More detailed estimate data can be found on the Atea Pharmaceuticals Inc (AVIR) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, Atea Pharmaceuticals Inc's (AVIR, Financial) average brokerage recommendation is currently 2.7, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
